Lineage Cell Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Lineage Cell Therapeutics, Inc. (LCTX) reported Increase (Decrease) in Contract with Customer, Liability of -$5.08 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-08-10
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was -$2.96M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was -$2.12M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-12-31 was -$1.76M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-09-30 was -$2.59M, a 814.36% decline year-over-year.
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$13.35M, a 3614.21% decline from fiscal 2021.
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was $380.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2018 was -$143.00K, a 158.85% decline from fiscal 2017.
- Lineage Cell Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2017 was $243.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2023-06-30 | -$2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$5.08M 10-Q · filed 2023-08-10 | -$6.84M derived: sum of 3 quarters · filed 2023-08-10 | -$9.43M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2023-03-31 | -$2.12M 10-Q · filed 2023-05-11 | -$3.88M derived: sum of 2 quarters · filed 2023-05-11 | -$6.47M derived: sum of 3 quarters · filed 2023-05-11 | -$10.61M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$4.35M derived: sum of 2 quarters · filed 2023-03-09 | -$8.49M derived: sum of 3 quarters · filed 2023-08-10 | -$13.35M 10-K · filed 2023-03-09 | |
| 2022-09-30 | -$2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$6.73M derived: sum of 2 quarters · filed 2023-08-10 | -$11.59M 10-Q · filed 2022-11-10 | -$11.99M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-06-30 | -$4.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$9.01M 10-Q · filed 2023-08-10 | -$9.41M derived: sum of 3 quarters · filed 2023-08-10 | -$9.05M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$4.87M 10-Q · filed 2023-05-11 | -$5.27M derived: sum of 2 quarters · filed 2023-05-11 | -$4.91M derived: sum of 3 quarters · filed 2023-05-11 | -$4.40M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$42.00K derived: sum of 2 quarters · filed 2023-03-09 | $466.00K derived: sum of 3 quarters · filed 2023-03-09 | $380.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $870.00K derived: sum of 2 quarters · filed 2022-11-10 | $784.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $508.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $422.00K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$86.00K 10-Q · filed 2022-05-12 | ||||
| 2020-06-30 | -$116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $51.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $167.00K 10-Q · filed 2021-05-13 | ||||
| 2019-09-30 | $132.00K 10-Q · filed 2020-11-04 | ||||
| 2019-03-31 | -$378.00K 10-Q · filed 2019-05-09 | -$317.00K derived: sum of 2 quarters · filed 2020-03-12 | -$451.00K derived: sum of 3 quarters · filed 2020-03-12 | -$567.00K derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$73.00K derived: sum of 2 quarters · filed 2020-03-12 | -$189.00K derived: sum of 3 quarters · filed 2020-03-12 | -$143.00K 10-K · filed 2020-03-12 | -$287.00K 10-K · filed 2019-03-14 |
| 2018-09-30 | -$134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$250.00K derived: sum of 2 quarters · filed 2019-11-12 | -$204.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$70.00K 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $46.00K 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | $243.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |